

Nicholas Cross

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/230047/publications.pdf>

Version: 2024-02-01

285
papers

32,163
citations

5430

85
h-index

5347

170
g-index

287
all docs

287
docs citations

287
times ranked

22940
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease. <i>Leukemia</i> , 2022, 36, 507-515.	3.3	49
2	Chronic Eosinophilic Leukaemia Associated with $JAK2$ Exon 13 Insertion/Deletion Mutations. <i>Acta Haematologica</i> , 2022, 145, 201-206.	0.7	2
3	Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 1783-1794.	0.8	24
4	Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. <i>Leukemia</i> , 2022, 36, 1834-1842.	3.3	10
5	Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. <i>American Journal of Human Genetics</i> , 2021, 108, 284-294.	2.6	12
6	Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2562.	1.8	9
7	Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. <i>Leukemia</i> , 2021, 35, 2445-2459.	3.3	36
8	The use of genetic tests to diagnose and manage patients with myeloproliferative and myelodysplastic neoplasms, and related disorders. <i>British Journal of Haematology</i> , 2021, 195, 338-351.	1.2	8
9	Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. <i>British Journal of Haematology</i> , 2021, 192, 62-74.	1.2	18
10	HGNC nomenclature for fusion genes. <i>Leukemia</i> , 2021, 35, 3039-3039.	3.3	1
11	HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. <i>Leukemia</i> , 2021, 35, 3040-3043.	3.3	42
12	A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 191, 171-193.	1.2	38
13	Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. <i>Leukemia</i> , 2020, 34, 2113-2124.	3.3	22
14	Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. <i>Leukemia</i> , 2020, 34, 2660-2672.	3.3	96
15	Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2279-2284.	3.3	7
16	Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. <i>Leukemia</i> , 2020, 34, 3206-3214.	3.3	8
17	A Novel $t(1;9)(p36;p24.1)$ $JAK2$ Translocation and Review of the Literature. <i>Acta Haematologica</i> , 2019, 142, 105-112.	0.7	5
18	Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. <i>Leukemia</i> , 2019, 33, 1195-1205.	3.3	38

#	ARTICLE	IF	CITATIONS
19	Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. <i>Leukemia</i> , 2019, 33, 415-425.	3.3	65
20	PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasia. <i>Leukemia</i> , 2019, 33, 1184-1194.	3.3	11
21	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. <i>Leukemia</i> , 2019, 33, 1124-1134.	3.3	29
22	Routine Screening for <i>CD34</i> and <i>KIT</i> ; M541L Is Not Warranted in the Diagnostic Work-Up of Patients with Hypereosinophilia. <i>Acta Haematologica</i> , 2018, 139, 71-73.	0.7	5
23	Consensus on <i>BCR-ABL1</i> reporting in chronic myeloid leukaemia in the UK. <i>British Journal of Haematology</i> , 2018, 182, 777-788.	1.2	11
24	Absence of <i>CALR</i> ; Mutations in Idiopathic Erythrocytosis Patients with Low Serum Erythropoietin Levels. <i>Acta Haematologica</i> , 2018, 139, 217-219.	0.7	3
25	Guideline for the investigation and management of eosinophilia. <i>British Journal of Haematology</i> , 2017, 176, 553-572.	1.2	110
26	Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1225-1233.	1.2	9
27	The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. <i>Haematologica</i> , 2017, 102, 1035-1043.	1.7	84
28	Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. <i>Blood</i> , 2017, 130, 137-145.	0.6	97
29	The effect of initial molecular profile on response to recombinant interferon- γ (rIFN γ) treatment in early myelofibrosis. <i>Cancer</i> , 2017, 123, 2680-2687.	2.0	48
30	Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1585-1596.	1.2	29
31	Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent <i>CSF3R</i> mutations in chronic neutrophilic leukemia. <i>Haematologica</i> , 2017, 102, e238-e240.	1.7	38
32	Measurement of <i>BCR-ABL1</i> by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme. <i>British Journal of Haematology</i> , 2017, 177, 414-422.	1.2	16
33	A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5). <i>Acta Haematologica</i> , 2017, 138, 198-200.	0.7	5
34	Genomics of Myeloproliferative Neoplasms. <i>Journal of Clinical Oncology</i> , 2017, 35, 947-954.	0.8	62
35	The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. <i>Journal of Clinical Investigation</i> , 2017, 127, 2206-2221.	3.9	69
36	Exon-centric regulation of ATM expression is population-dependent and amenable to antisense modification by pseudoexon targeting. <i>Scientific Reports</i> , 2016, 6, 18741.	1.6	5

#	ARTICLE	IF	CITATIONS
37	Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. <i>Leukemia</i> , 2016, 30, 1844-1852.	3.3	51
38	Antisense Oligonucleotides Modulating Activation of a Nonsense-Mediated RNA Decay Switch Exon in the ATM Gene. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 392-400.	2.0	9
39	Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators. <i>Leukemia</i> , 2016, 30, 2258-2260.	3.3	12
40	Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. <i>European Journal of Clinical Investigation</i> , 2016, 46, 392-397.	1.7	21
41	Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. <i>Leukemia</i> , 2016, 30, 2342-2350.	3.3	73
42	Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation. <i>Annals of Hematology</i> , 2016, 95, 557-562.	0.8	27
43	Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis. <i>Leukemia</i> , 2016, 30, 136-143.	3.3	185
44	Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. <i>Leukemia</i> , 2016, 30, 57-64.	3.3	91
45	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. <i>Blood</i> , 2015, 125, 1857-1865.	0.6	153
46	Neutrophilic leukemoid reaction in multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 1090-1090.	2.0	3
47	<sc><i>KIT</i></sc><sc><i>D</i></sc><i>816</i><sc><i>V</i></sc> and <sc><i>JAK</i></sc><i>2</i><sc><i>V</i></sc><i>617</i><sc><i>F</i></sc> mutations are seen recurrently in hypereosinophilia of unknown significance. <i>American Journal of Hematology</i> , 2015, 90, 774-777.	2.0	50
48	Fusion of <i>PDGFRB</i> to <i>MPRIIP, CPSF6</i>, and <i>GOLGB1</i> in three patients with eosinophilia-associated myeloproliferative neoplasms. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 762-770.	1.5	27
49	Identification of U2AF(35)-dependent exons by RNA-Seq reveals a link between 3' splice-site organization and activity of U2AF-related proteins. <i>Nucleic Acids Research</i> , 2015, 43, 3747-3763.	6.5	35
50	Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. <i>Annals of Hematology</i> , 2015, 94, 233-238.	0.8	74
51	Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. <i>Leukemia</i> , 2015, 29, 999-1003.	3.3	280
52	Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. <i>Nature Communications</i> , 2015, 6, 5901.	5.8	196
53	Detection of leukemia-associated mutations in peripheral blood DNA of hematologically normal elderly individuals. <i>Leukemia</i> , 2015, 29, 1600-1602.	3.3	16
54	Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. <i>Leukemia</i> , 2015, 29, 1115-1122.	3.3	134

#	ARTICLE	IF	CITATIONS
55	Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Haematologica</i> , 2015, 100, e237-e239.	1.7	21
56	KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. <i>Leukemia</i> , 2015, 29, 1223-1232.	3.3	229
57	An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. <i>Haematologica</i> , 2015, 100, 1117-1130.	1.7	97
58	Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus. <i>Leukemia</i> , 2015, 29, 2069-2074.	3.3	13
59	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. <i>Nature Communications</i> , 2015, 6, 6691.	5.8	145
60	Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. <i>Leukemia Research</i> , 2015, 39, 82-87.	0.4	55
61	A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. <i>Leukemia</i> , 2015, 29, 369-376.	3.3	72
62	Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. <i>International Journal of Hematology</i> , 2015, 101, 229-242.	0.7	56
63	A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. <i>Leukemia</i> , 2014, 28, 1570-1572.	3.3	34
64	Identification and functional characterization of imatinib-sensitive <i>DTD1-PTGFRB</i> and <i>CCDC88C-PTGFRB</i> fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 411-421.	1.5	23
65	Patients with myeloid malignancies bearing <i>PTGFRB</i> fusion genes achieve durable long-term remissions with imatinib. <i>Blood</i> , 2014, 123, 3574-3577.	0.6	118
66	Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. <i>Nature Genetics</i> , 2014, 46, 624-628.	9.4	320
67	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. <i>Leukemia</i> , 2014, 28, 1804-1810.	3.3	263
68	The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. <i>Annals of Hematology</i> , 2014, 93, 81-88.	0.8	142
69	Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. <i>British Journal of Haematology</i> , 2014, 167, 421-423.	1.2	40
70	The future of JAK inhibition in myelofibrosis and beyond. <i>Blood Reviews</i> , 2014, 28, 189-196.	2.8	25
71	Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling. <i>Leukemia</i> , 2014, 28, 2106-2109.	3.3	20
72	Megalencephaly Syndromes: Exome Pipeline Strategies for Detecting Low-Level Mosaic Mutations. <i>PLoS ONE</i> , 2014, 9, e86940.	1.1	20

#	ARTICLE	IF	CITATIONS
73	Mutations in <i>SETBP1</i> are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression. <i>British Journal of Haematology</i> , 2013, 163, 235-239.	1.2	37
74	Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients. <i>Leukemia</i> , 2013, 27, 2105-2107.	3.3	23
75	Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. <i>Leukemia</i> , 2013, 27, 2032-2039.	3.3	96
76	Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i> . <i>New England Journal of Medicine</i> , 2013, 369, 2391-2405.	13.9	1,556
77	JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. <i>Leukemia</i> , 2013, 27, 1763-1767.	3.3	24
78	Clinical and biological implications of driver mutations in myelodysplastic syndromes. <i>Blood</i> , 2013, 122, 3616-3627.	0.6	1,562
79	The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. <i>Blood</i> , 2013, 121, 468-475.	0.6	190
80	Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. <i>Nature Genetics</i> , 2013, 45, 18-24.	9.4	359
81	Recurrent <i>CEP85L</i> PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1527-1531.	0.6	10
82	Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 2428-2436.	0.8	462
83	Comprehensive mutational profiling in advanced systemic mastocytosis. <i>Blood</i> , 2013, 122, 2460-2466.	0.6	222
84	Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of <i>JAK2</i> and <i>V617F</i> and other relevant mutations. <i>British Journal of Haematology</i> , 2013, 160, 25-34.	1.2	87
85	Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale. <i>Clinical Chemistry</i> , 2013, 59, 938-948.	1.5	46
86	Why do we see JAK2 exon 12 mutations in myeloproliferative neoplasms?. <i>Leukemia</i> , 2013, 27, 1930-1932.	3.3	4
87	Mutations and prognosis in primary myelofibrosis. <i>Leukemia</i> , 2013, 27, 1861-1869.	3.3	653
88	Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. <i>Haematologica</i> , 2013, 98, 103-106.	1.7	70
89	Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. <i>Leukemia</i> , 2013, 27, 2254-2256.	3.3	61
90	Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements. <i>Haematologica</i> , 2013, 98, 404-408.	1.7	35

#	ARTICLE	IF	CITATIONS
91	Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. <i>Haematologica</i> , 2013, 98, 576-583.	1.7	9
92	Impact of isolated germline JAK2V617I mutation on human hematopoiesis. <i>Blood</i> , 2013, 121, 4156-4165.	0.6	42
93	Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. <i>Haematologica</i> , 2013, 98, 1414-1420.	1.7	46
94	Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFR α positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. <i>Leukemia</i> , 2012, 26, 162-164.	3.3	55
95	Philadelphia Chromosome-Negative Myeloproliferative Neoplasm With a Novel Platelet-Derived Growth Factor Receptor- β Rearrangement Responsive to Imatinib. <i>Journal of Clinical Oncology</i> , 2012, 30, e109-e111.	0.8	4
96	Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. <i>Haematologica</i> , 2012, 97, 538-542.	1.7	31
97	Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2012, 119, 1208-1213.	0.6	162
98	Activating CBL mutations are associated with a distinct MDS/MPN phenotype. <i>Annals of Hematology</i> , 2012, 91, 1713-1720.	0.8	29
99	TET2 Mutations Are Associated with Specific 5-Methylcytosine and 5-Hydroxymethylcytosine Profiles in Patients with Chronic Myelomonocytic Leukemia. <i>PLoS ONE</i> , 2012, 7, e31605.	1.1	70
100	Acquired Uniparental Disomy in Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 981-991.	0.9	14
101	Standardized definitions of molecular response in chronic myeloid leukemia. <i>Leukemia</i> , 2012, 26, 2172-2175.	3.3	339
102	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. <i>Blood</i> , 2012, 119, 3211-3218.	0.6	220
103	Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR- FGFR1 gene fusion. <i>Pediatric Blood and Cancer</i> , 2012, 59, 194-196.	0.8	25
104	Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. <i>Leukemia</i> , 2011, 25, 877-879.	3.3	131
105	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. <i>Blood</i> , 2011, 118, 1208-1215.	0.6	486
106	Novel imatinib-sensitive PDGFR α -activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. <i>Blood</i> , 2011, 117, 2935-2943.	0.6	76
107	Response of ETV6-FLT3 ITD -positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. <i>Blood</i> , 2011, 118, 2239-2242.	0.6	75
108	EZH2 mutational status predicts poor survival in myelofibrosis. <i>Blood</i> , 2011, 118, 5227-5234.	0.6	242

#	ARTICLE	IF	CITATIONS
109	The European LeukemiaNet: achievements and perspectives. <i>Haematologica</i> , 2011, 96, 156-162.	1.7	15
110	Identification of <i>FOXP1</i> and <i>SNX2</i> as novel <i>ABL1</i> fusion partners in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2011, 153, 43-46.	1.2	40
111	Guidelines for the measurement of <i>BCR-ABL1</i> transcripts in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2011, 153, 179-190.	1.2	94
112	IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. <i>Leukemia</i> , 2011, 25, 178-181.	3.3	27
113	The t(4;9)(q11;q33) fuses CEP110 to KIT in a case of acute myeloid leukemia. <i>Leukemia</i> , 2011, 25, 1049-1050.	3.3	2
114	The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia. <i>Annals of Hematology</i> , 2011, 90, 365-366.	0.8	6
115	JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. <i>Leukemia Research</i> , 2011, 35, 177-182.	0.4	56
116	Aberrations of <i>EZH2</i> in Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2613-2618.	3.2	503
117	Impact of <i>BCR-ABL</i> mutations on patients with chronic myeloid leukemia. <i>Cell Cycle</i> , 2011, 10, 250-260.	1.3	64
118	TFC, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals. <i>Haematologica</i> , 2010, 95, 20-26.	1.7	63
119	Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. <i>Haematologica</i> , 2010, 95, 1473-1480.	1.7	67
120	A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon α . <i>Haematologica</i> , 2010, 95, 148-152.	1.7	29
121	Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. <i>Haematologica</i> , 2010, 95, 738-744.	1.7	72
122	The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. <i>Haematologica</i> , 2010, 95, 1221-1225.	1.7	84
123	In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. <i>Blood</i> , 2010, 116, 1329-1335.	0.6	78
124	Atypical mRNA fusions in <i>PML-RARA</i> positive, <i>RARA-PML</i> negative acute promyelocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 471-479.	1.5	26
125	Analysis of genomic breakpoints in p190 and p210 <i>BCR-ABL</i> indicate distinct mechanisms of formation. <i>Leukemia</i> , 2010, 24, 1742-1750.	3.3	43
126	Inactivating mutations of the histone methyltransferase gene <i>EZH2</i> in myeloid disorders. <i>Nature Genetics</i> , 2010, 42, 722-726.	9.4	1,034

#	ARTICLE	IF	CITATIONS
127	Interlaboratory Diagnostic Validation of Conformation-Sensitive Capillary Electrophoresis for Mutation Scanning. <i>Clinical Chemistry</i> , 2010, 56, 593-602.	1.5	11
128	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. <i>Blood</i> , 2010, 116, e111-e117.	0.6	141
129	No association between myeloproliferative neoplasms and the Crohn's disease-associated STAT3 predisposition SNP rs744166. <i>Haematologica</i> , 2010, 95, 1226-1227.	1.7	3
130	The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. <i>Blood</i> , 2010, 115, 4517-4523.	0.6	93
131	Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. <i>Haematologica</i> , 2009, 94, 1024-1028.	1.7	47
132	Molecular basis of myelodysplastic/myeloproliferative neoplasms. <i>Haematologica</i> , 2009, 94, 1634-1638.	1.7	41
133	Frequent upregulation of MYC in plasma cell leukemia. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 624-636.	1.5	65
134	No evidence for increased prevalence of JAK2 V617F in women with a history of recurrent miscarriage. <i>British Journal of Haematology</i> , 2009, 144, 802-803.	1.2	12
135	Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. <i>British Journal of Haematology</i> , 2009, 144, 904-908.	1.2	75
136	Acute myeloid leukaemia with associated eosinophilia: justification for FIP1L1-PDGFR α screening in cases lacking the CBF β -MYH11 fusion gene. <i>British Journal of Haematology</i> , 2009, 146, 225-227.	1.2	11
137	Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1. <i>Leukemia</i> , 2009, 23, 358-364.	3.3	13
138	Detection and molecular monitoring of FIP1L1-PDGFR α -positive disease by analysis of patient-specific genomic DNA fusion junctions. <i>Leukemia</i> , 2009, 23, 332-339.	3.3	35
139	The molecular anatomy of the FIP1L1-PDGFR α fusion gene. <i>Leukemia</i> , 2009, 23, 271-278.	3.3	23
140	Harmonization of molecular monitoring of CML therapy in Europe. <i>Leukemia</i> , 2009, 23, 1957-1963.	3.3	196
141	Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder. <i>Bone Marrow Transplantation</i> , 2009, 44, 197-199.	1.3	4
142	JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. <i>Nature Genetics</i> , 2009, 41, 446-449.	9.4	365
143	Standardisation of molecular monitoring for chronic myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 355-365.	0.7	85
144	Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. <i>Haematologica</i> , 2009, 94, 1708-1713.	1.7	68

#	ARTICLE	IF	CITATIONS
145	Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. <i>Blood</i> , 2009, 113, 6182-6192.	0.6	349
146	Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia. <i>International Journal of Hematology</i> , 2008, 88, 197-201.	0.7	11
147	The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins <i>SFPO (PSF)</i> and <i>CPSF6</i> to <i>ABL</i> and <i>FGFR1</i> . <i>Genes Chromosomes and Cancer</i> , 2008, 47, 379-385.	1.5	55
148	International standardisation of quantitative real-time RT-PCR for BCR-ABL. <i>Leukemia Research</i> , 2008, 32, 505-506.	0.4	30
149	Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. <i>Leukemia</i> , 2008, 22, 1320-1334.	3.3	24
150	BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. <i>Leukemia</i> , 2008, 22, 1975-1989.	3.3	21
151	JAK2 Mutations are present in all cases of polycythemia vera. <i>Leukemia</i> , 2008, 22, 1289-1289.	3.3	53
152	Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase III study. <i>British Journal of Haematology</i> , 2008, 143, 707-715.	1.2	128
153	Fibroblast Growth Factor Receptor and Platelet-Derived Growth Factor Receptor Abnormalities in Eosinophilic Myeloproliferative Disorders. <i>Acta Haematologica</i> , 2008, 119, 199-206.	0.7	59
154	Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. <i>Haematologica</i> , 2008, 93, 1560-1564.	1.7	49
155	Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. <i>Blood</i> , 2008, 112, 3330-3338.	0.6	350
156	Chronic Myeloproliferative Disorders: The Role of Tyrosine Kinases in Pathogenesis, Diagnosis and Therapy. <i>Pathobiology</i> , 2007, 74, 81-88.	1.9	29
157	Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. <i>Blood</i> , 2007, 109, 61-64.	0.6	156
158	Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. <i>Blood</i> , 2007, 110, 3729-3734.	0.6	91
159	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRB-positive chronic eosinophilic leukemia. <i>Blood</i> , 2007, 109, 4635-4640.	0.6	195
160	Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. <i>Blood</i> , 2007, 110, 1283-1290.	0.6	72
161	Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. <i>Blood</i> , 2007, 110, 3291-3300.	0.6	133
162	Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders. <i>Current Drug Targets</i> , 2007, 8, 205-216.	1.0	30

#	ARTICLE	IF	CITATIONS
163	Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 272-276.	1.2	60
164	Methylation-Sensitive High-Resolution Melting-Curve Analysis of the SNRPN Gene as a Diagnostic Screen for Prader-Willi and Angelman Syndromes. <i>Clinical Chemistry</i> , 2007, 53, 1960-1962.	1.5	87
165	Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor A gene. <i>Haematologica</i> , 2007, 92, 163-169.	1.7	84
166	Evaluation of <i>JAK2</i> ^{V617F} in B and T Cell Neoplasms: Identification of <i>JAK2</i> ^{V617F} Mutation of Undetermined Significance (JMUS) in the Bone Marrow of Three Individuals. <i>Acta Haematologica</i> , 2007, 118, 209-214.	0.7	17
167	FIP1L1-PDGFR α in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. <i>Leukemia</i> , 2007, 21, 397-402.	3.3	21
168	Recurrent finding of the FIP1L1-PDGFR α fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. <i>Leukemia</i> , 2007, 21, 1183-1188.	3.3	170
169	A novel ETV6-PDGFR β fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. <i>Leukemia</i> , 2007, 21, 1839-1841.	3.3	33
170	Chronic myeloid leukemia – some topical issues. <i>Leukemia</i> , 2007, 21, 1347-1352.	3.3	12
171	The severity of FIP1L1-PDGFR α -positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. <i>Leukemia</i> , 2007, 21, 2428-2432.	3.3	26
172	Two novel imatinib-responsive PDGFR α fusion genes in chronic eosinophilic leukaemia. <i>British Journal of Haematology</i> , 2007, 138, 77-81.	1.2	79
173	A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. <i>Experimental Hematology</i> , 2007, 35, 1723-1727.	0.2	44
174	Simultaneous MLPA-based multiplex point mutation and deletion analysis of the Dystrophin gene. <i>Molecular Biotechnology</i> , 2007, 35, 135-140.	1.3	24
175	Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders. <i>Haematologica</i> , 2007, 92, 1153-1158.	1.7	14
176	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , 2006, 108, 28-37.	0.6	1,117
177	Eosinophilic disorders: Molecular pathogenesis, new classification, and modern therapy. <i>Best Practice and Research in Clinical Haematology</i> , 2006, 19, 535-569.	0.7	60
178	Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases. <i>Clinical Science</i> , 2006, 111, 233-249.	1.8	10
179	Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. <i>Blood</i> , 2006, 107, 4171-4176.	0.6	119
180	Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. <i>Blood</i> , 2006, 107, 3339-3341.	0.6	113

#	ARTICLE	IF	CITATIONS
181	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). <i>Blood</i> , 2006, 108, 1497-1503.	0.6	317
182	JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. <i>Leukemia</i> , 2006, 20, 534-535.	3.3	41
183	Identification of a novel imatinib responsive KIF5B-PDGFR A fusion gene following screening for PDGFR A overexpression in patients with hypereosinophilia. <i>Leukemia</i> , 2006, 20, 827-832.	3.3	122
184	Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. <i>Leukemia</i> , 2006, 20, 1610-1617.	3.3	141
185	JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?. <i>Leukemia</i> , 2006, 20, 2067-2067.	3.3	45
186	Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. <i>Leukemia</i> , 2006, 20, 1925-1930.	3.3	184
187	A novel K509I mutation of KIT identified in familial mastocytosisâ€”in vitro and in vivo responsiveness to imatinib therapy. <i>Leukemia Research</i> , 2006, 30, 373-378.	0.4	129
188	Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and aCDK5RAP2-PDGFR A fusion gene. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 950-956.	1.5	72
189	Cough and hypereosinophilia due to FIP1L1-PDGFR A fusion gene with tyrosine kinase activity. <i>European Respiratory Journal</i> , 2006, 27, 230-232.	3.1	37
190	Idiopathic Hypereosinophilic Syndrome in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 663-665.	0.3	38
191	NUP98-LEDGF fusion and t(9;11) in transformed chronic myeloid leukemia. <i>Leukemia Research</i> , 2005, 29, 1469-1472.	0.4	28
192	Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2005, 130, 229-232.	1.2	47
193	Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. <i>Leukemia</i> , 2005, 19, 245-252.	3.3	69
194	Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript. <i>Leukemia</i> , 2005, 19, 1096-1099.	3.3	20
195	The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. <i>Leukemia</i> , 2005, 19, 1005-1009.	3.3	85
196	Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. <i>Leukemia</i> , 2005, 19, 1634-1642.	3.3	73
197	Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: Results at 4 years. <i>International Journal of Cancer</i> , 2005, 114, 94-100.	2.3	63
198	DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2005, 352, 1529-1538.	13.9	262

#	ARTICLE	IF	CITATIONS
199	The t(8;9)(p22;p24) Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses PCM1 to JAK2. <i>Cancer Research</i> , 2005, 65, 2662-2667.	0.4	269
200	Accurate Detection and Quantitation of Heteroplasmic Mitochondrial Point Mutations by Pyrosequencing. <i>Genetic Testing and Molecular Biomarkers</i> , 2005, 9, 190-199.	1.7	94
201	Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. <i>Blood</i> , 2005, 106, 2162-2168.	0.6	798
202	Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia. <i>New England Journal of Medicine</i> , 2005, 353, 33-45.	13.9	838
203	p53-Binding Protein 1 Is Fused to the Platelet-Derived Growth Factor Receptor $\hat{1}^2$ in a Patient with a t(5;15)(q33;q22) and an Imatinib-Responsive Eosinophilic Myeloproliferative Disorder. <i>Cancer Research</i> , 2004, 64, 7216-7219.	0.4	74
204	NIN, a Gene Encoding a CEP110-Like Centrosomal Protein, Is Fused to PDGFRB in a Patient with a t(5;14)(q33;q24) and an Imatinib-Responsive Myeloproliferative Disorder 1. <i>Cancer Research</i> , 2004, 64, 2673-2676.	0.4	67
205	Critical Role of STAT5 Activation in Transformation Mediated by ZNF198-FGFR1. <i>Journal of Biological Chemistry</i> , 2004, 279, 6666-6673.	1.6	43
206	Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2004, 126, 508-511.	1.2	12
207	Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. <i>Leukemia</i> , 2004, 18, 962-966.	3.3	137
208	Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. <i>British Journal of Cancer</i> , 2004, 91, 1155-1159.	2.9	161
209	Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. <i>Cancer Cell</i> , 2004, 5, 287-298.	7.7	145
210	Oncogenic protein tyrosine kinases. <i>Cellular and Molecular Life Sciences</i> , 2004, 61, 2912-2923.	2.4	126
211	Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome. <i>Genes Chromosomes and Cancer</i> , 2004, 40, 78-83.	1.5	89
212	Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases. <i>The Hematology Journal</i> , 2004, 5, 534-537.	2.0	49
213	Paucimorphic Alleles versus Polymorphic Alleles and Rare Mutations in Disease Causation: Theory, Observation and Detection. <i>Current Genomics</i> , 2004, 5, 431-438.	0.7	7
214	MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. <i>Cancer Cell</i> , 2003, 3, 259-271.	7.7	192
215	Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2003, 36, 175-188.	1.5	58
216	Novel translocations that disrupt the platelet-derived growth factor receptor $\hat{1}^2$ (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. <i>British Journal of Haematology</i> , 2003, 120, 251-256.	1.2	87

#	ARTICLE	IF	CITATIONS
217	P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12. <i>Leukemia</i> , 2003, 17, 2097-2100.	3.3	42
218	Imatinib for systemic mast-cell disease. <i>Lancet</i> , The, 2003, 362, 535-537.	6.3	242
219	A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome. <i>New England Journal of Medicine</i> , 2003, 348, 1201-1214.	13.9	1,655
220	Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. <i>Blood</i> , 2003, 101, 3391-3397.	0.6	206
221	CHIC2 deletion, a surrogate for FIP1L1-PDGFR A fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. <i>Blood</i> , 2003, 102, 3093-3096.	0.6	368
222	The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. <i>Human Molecular Genetics</i> , 2002, 11, 1391-1397.	1.4	139
223	Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta. <i>New England Journal of Medicine</i> , 2002, 347, 481-487.	13.9	623
224	The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of <i>FGFR1</i> . <i>Acta Haematologica</i> , 2002, 107, 101-107.	0.7	220
225	Chronic Eosinophilic Leukaemia Presenting with Erythroderma, Mild Eosinophilia and Hyper-IgE: Clinical, Immunological and Cytogenetic Features and Therapeutic Approach. <i>Acta Haematologica</i> , 2002, 107, 108-112.	0.7	27
226	Myeloproliferative Disorders with Translocations of Chromosome 5q31-q35: Role of the Platelet-Derived Growth Factor Receptor Beta. <i>Acta Haematologica</i> , 2002, 107, 113-122.	0.7	170
227	Tyrosine kinase fusion genes in chronic myeloproliferative diseases. <i>Leukemia</i> , 2002, 16, 1207-1212.	3.3	124
228	Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. <i>Leukemia</i> , 2002, 16, 2190-2196.	3.3	839
229	Myeloproliferative disorders. <i>Best Practice and Research in Clinical Haematology</i> , 2001, 14, 531-551.	0.7	39
230	Cytogenetics of chronic myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2001, 14, 553-571.	0.7	36
231	ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. <i>Blood</i> , 2001, 98, 2879-2880.	0.6	38
232	Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. <i>Blood</i> , 2001, 97, 1560-1565.	0.6	154
233	The influence of INK4 proteins on growth and self-renewal kinetics of hematopoietic progenitor cells. <i>Blood</i> , 2001, 97, 2604-2610.	0.6	46
234	The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. <i>Blood</i> , 2001, 98, 3778-3783.	0.6	189

#	ARTICLE	IF	CITATIONS
235	A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. <i>Blood</i> , 2001, 98, 1264-1267.	0.6	245
236	Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. <i>British Journal of Haematology</i> , 2001, 115, 569-574.	1.2	66
237	Identification of four new translocations involving FGFR1 in myeloid disorders. <i>Genes Chromosomes and Cancer</i> , 2001, 32, 155-163.	1.5	91
238	Mutations of the transcription factor AML1/CBA2 are uncommon in blastic transformation of chronic myeloid leukaemia. <i>Leukemia</i> , 2001, 15, 476-477.	3.3	8
239	Detection and quantification of residual disease in chronic myelogenous leukemia. <i>Leukemia</i> , 2000, 14, 998-1005.	3.3	105
240	Cloning of ZNF237, a novel member of the MYM gene family that maps to human chromosome 13q11-q12. <i>Cytogenetic and Genome Research</i> , 2000, 89, 24-28.	0.6	5
241	Assignment of ZNF262 to human chromosome band 1p34-p32 by in situ hybridization. <i>Cytogenetic and Genome Research</i> , 1999, 85, 306-307.	0.6	7
242	A case of myelofibrosis with a t(4;13)(q25;q12): evidence for involvement of a second 13q12 locus in chronic myeloproliferative disorders. <i>British Journal of Haematology</i> , 1999, 105, 771-774.	1.2	7
243	Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. <i>British Journal of Haematology</i> , 1999, 106, 634-643.	1.2	50
244	Two patients with novel BCR/ABL fusion transcripts (e8/a2 and e13/a2) resulting from translocation breakpoints within BCR exons. <i>British Journal of Haematology</i> , 1999, 105, 434-436.	1.2	28
245	Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. <i>Leukemia</i> , 1999, 13, 1825-1832.	3.3	255
246	Consistent Fusion of MOZ and TIF2 in AML with inv(8)(p11q13). <i>Cancer Genetics and Cytogenetics</i> , 1999, 113, 70-72.	1.0	50
247	The Genomic Structure of ZNF198 and Location of Breakpoints in the t(8;13) Myeloproliferative Syndrome. <i>Genomics</i> , 1999, 55, 118-121.	1.3	24
248	Cloning and Characterization of RNF6, a Novel RING Finger Gene Mapping to 13q12. <i>Genomics</i> , 1999, 58, 94-97.	1.3	20
249	Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. <i>Bone Marrow Transplantation</i> , 1998, 21, 1055-1061.	1.3	67
250	Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells. <i>British Journal of Cancer</i> , 1998, 78, 601-605.	2.9	10
251	BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon- γ . <i>British Journal of Haematology</i> , 1998, 102, 1271-1278.	1.2	18
252	A novel BCR-ABL fusion gene (e2/1a) in a patient with Philadelphia-positive chronic myelogenous leukaemia and an aggressive clinical course. <i>British Journal of Haematology</i> , 1998, 103, 791-794.	1.2	22

#	ARTICLE	IF	CITATIONS
253	Assignment of the Steroid Receptor Coactivator-1 (SRC-1) Gene to Human Chromosome Band 2p23. <i>Genomics</i> , 1998, 52, 242-244.	1.3	10
254	The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster. <i>Leukemia</i> , 1997, 11, 233-238.	3.3	29
255	An extremely delayed cytogenetic response to interferon- α in a patient with chronic myeloid leukaemia. <i>Leukemia</i> , 1997, 11, 614-616.	3.3	2
256	Rarity of dominant-negative mutations of the G-CSF receptor in patients with blast crisis of chronic myeloid leukemia or de novo acute leukemia. <i>Leukemia</i> , 1997, 11, 1005-1008.	3.3	24
257	Molecular response of CML patients treated with interferon- α monitored by quantitative Southern blot analysis. <i>British Journal of Haematology</i> , 1997, 97, 86-93.	1.2	34
258	The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 1997, 99, 945-950.	1.2	72
259	Rarity of microsatellite alterations in acute myeloid leukaemia. <i>British Journal of Cancer</i> , 1996, 74, 255-257.	2.9	37
260	Mutational analysis of the p15 and p16 genes in acute leukaemias. <i>British Journal of Haematology</i> , 1996, 92, 681-683.	1.2	22
261	Quantification of PML-RAR α transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia-specific mRNA by alpha interferon. <i>British Journal of Haematology</i> , 1996, 95, 95-101.	1.2	40
262	TEL-AML1 fusion in acute lymphoblastic leukaemia of adults. <i>British Journal of Haematology</i> , 1996, 95, 673-677.	1.2	86
263	Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR. <i>British Journal of Haematology</i> , 1995, 90, 138-146.	1.2	63
264	Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon- α . <i>British Journal of Haematology</i> , 1995, 91, 126-131.	1.2	75
265	Localization of the 8;13 translocation breakpoint associated with myeloproliferative disease to a 1.5 mbp region of chromosome 13. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 283-287.	1.5	25
266	Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia. <i>Genes Chromosomes and Cancer</i> , 1995, 13, 110-114.	1.5	22
267	Null alleles of the aldolase B gene in patients with hereditary fructose intolerance.. <i>Journal of Medical Genetics</i> , 1994, 31, 499-503.	1.5	18
268	A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 1994, 86, 683-685.	1.2	56
269	An atypical myeloproliferative disorder with t(8;13) (p11;q12): a third case. <i>British Journal of Haematology</i> , 1994, 86, 879-880.	1.2	48
270	APPROPRIATE CONTROLS FOR REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR). <i>British Journal of Haematology</i> , 1994, 87, 218-218.	1.2	18

#	ARTICLE	IF	CITATIONS
271	Aplasia after donor lymphocyte infusion (DLI) for CML in relapse after sex-mismatched BMT: recovery of donor-type haemopoiesis predicted by non-isotopic in situ hybridization (ISH). <i>British Journal of Haematology</i> , 1994, 88, 400-402.	1.2	14
272	Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. <i>British Journal of Haematology</i> , 1993, 84, 67-74.	1.2	159
273	Isolation and characterization of the genes encoding mouse and human type-5 acid phosphatase. <i>Gene</i> , 1993, 130, 201-207.	1.0	46
274	BCR-ABL antisense purging in chronic myeloid leukaemia. <i>Lancet, The</i> , 1993, 342, 614.	6.3	35
275	Minimal Residual Disease after Bone Marrow Transplant for Chronic Myeloid Leukaemia Detected by the Polymerase Chain Reaction. <i>Leukemia and Lymphoma</i> , 1993, 11, 39-43.	0.6	57
276	Aldolase B mutations in Italian families affected by hereditary fructose intolerance.. <i>Journal of Medical Genetics</i> , 1991, 28, 241-243.	1.5	20
277	Type 5 acid phosphatase. Sequence, expression and chromosomal localization of a differentiation-associated protein of the human macrophage. <i>FEBS Journal</i> , 1990, 189, 287-293.	0.2	88
278	Hereditary fructose intolerance. <i>International Journal of Biochemistry & Cell Biology</i> , 1990, 22, 685-689.	0.8	12
279	A new aldolase B variant, N334K, is a common cause of hereditary fructose intolerance in Yugoslavia. <i>Nucleic Acids Research</i> , 1990, 18, 1925-1925.	6.5	29
280	Molecular analysis of aldolase B genes in hereditary fructose intolerance. <i>Lancet, The</i> , 1990, 335, 306-309.	6.3	127
281	Catalytic deficiency of human aldolase B in hereditary fructose intolerance caused by a common missense mutation. <i>Cell</i> , 1988, 53, 881-885.	13.5	98
282	A potent inhibitor of Taq polymerase copurifies with human genomic DNA. <i>Nucleic Acids Research</i> , 1988, 16, 10355-10355.	6.5	143
283	Polymerase chain reaction automated at low cost. <i>Nucleic Acids Research</i> , 1988, 16, 5687-5688.	6.5	22
284	Tsetse fly rDNA: an analysis of structure and sequence. <i>Nucleic Acids Research</i> , 1987, 15, 15-30.	6.5	40
285	A novel arrangement of sequence elements surrounding the rDNA promoter and its spacer duplications in tsetse species. <i>Journal of Molecular Biology</i> , 1987, 195, 63-74.	2.0	17